Autonomix Medical, Inc. will execute a 1-for-21 reverse stock split effective June 24, 2026. Every 21 shares of common stock will be consolidated into one share, reducing outstanding shares from approximately 11.4 million to 543,000 while the authorized share count remains at 500 million. Shares will begin trading on a post-split basis under the ticker AMIX with a new CUSIP number 05330T304, and no fractional shares will be issued, with cash payments made in lieu of fractions. The company also confirmed that shares reserved under its equity compensation plan will be proportionately reduced. Autonomix, based in The Woodlands, Texas, is developing a catheter-based microchip sensing array for neural signal detection, initially targeting pain management in pancreatic cancer.
Autonomix Medical, Inc. Common StockReverse stock split is a financial restructuring that often signals distress and reduces share count, typically viewed negatively by the market.